We use cookies to help provide and enhance our service and tailor content and advertisements. Disable them / read more. By continuing or closing this message you agree to the use of cookies.
AbbVie, Allergan well-positioned for unconditional clearance in Brazil
02 Apr 2020 12:41 pm by Ana Paula Candil
AbbVie’s $63 million merger with Allergan is well-positioned for unconditional antitrust clearance in Brazil, MLex has learned.
Approval by the Administrative Council for Economic Defense, or CADE, is expected to be announced soon.
AbbVie and Allergan submitted merger paperwork on Aug. 22, but amended their notification form, pushing the review deadline to Nov. 14.
AbbVie and Allergan are listed on the New York Stock Exchange.
Related Posts
-
The call for a merger moratorium due to the novel coronavirus pandemic likely won’t become law. -
The federal judge who approved T-Mobile's plan to buy Sprint said the usual presumptions in antitrust law don't work in this case because of the specifics of the dynamic, rapidly changing mobile wireless industry. -
Amazon.com and Deliveroo have a challenge ahead to defend their stake-purchase agreement by convincing the UK's competition regulator that they don't compete with each other — a finding that would require it to diverge from its established approach.